Patents by Inventor Magali Bourghol Hickey
Magali Bourghol Hickey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8809586Abstract: Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.Type: GrantFiled: December 6, 2012Date of Patent: August 19, 2014Assignee: Cephalon, Inc.Inventors: Magali Bourghol Hickey, Matthew Peterson, Orn Almarsson, Mark Oliveira
-
Patent number: 8436029Abstract: Crystalline salts, polymorphs, solvates, and hydrates of bicalutamide, 5-fluorouracil, donepezil, anastrozole, nelfinavir, mirtazapine, lansoprazole, and tamsulosin, or derivatives thereof are provided by the subject invention. Methods of making and using the same are also provided.Type: GrantFiled: March 17, 2005Date of Patent: May 7, 2013Assignees: Transform Pharmaceuticals, Inc., University of South FloridaInventors: Magali Bourghol Hickey, Matthew L. Peterson, Örn Almarsson, Michael J. Zaworotko, Tanise Shattock, Julius F. Remenar, Mark Tawa
-
Patent number: 8338646Abstract: Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.Type: GrantFiled: February 19, 2010Date of Patent: December 25, 2012Assignee: Cephalon, IncInventors: Magali Bourghol Hickey, Matthew Peterson, Orn Almarsson, Mark Oliveira
-
Publication number: 20120015993Abstract: Crystalline salts, polymorphs, solvates, and hydrates of bicalutamide, 5-fluorouracil, donepezil, anastrozole, nelfinavir, mirtazapine, lansoprazole, and tamsulosin, or derivatives thereof are provided by the subject invention. Methods of making and using the same are also provided.Type: ApplicationFiled: March 17, 2005Publication date: January 19, 2012Applicants: University of South Florida, TRANSFORM PHARMACEUTICALS, INC.Inventors: Magali Bourghol Hickey, Matthew L. Peterson, Örn Almarsson, Michael J. Zaworotko, Tanise Shattock, Jennifer McMahon, Joanna Bis, Julius F. Remenar, Mark Tawa
-
Patent number: 7927613Abstract: A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.Type: GrantFiled: September 11, 2003Date of Patent: April 19, 2011Assignees: University of South Florida, The Regents of the University of Michigan, Transform Pharmaceuticals, Inc.Inventors: Örn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson, Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
-
Publication number: 20100311701Abstract: A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.Type: ApplicationFiled: June 2, 2010Publication date: December 9, 2010Applicants: Transform Pharmaceuticals, Inc, University Of South Florida, The Regents of the University Of MichiganInventors: Orn Almarsson, Magali Bourghol Hickey, Matthew Peterson, Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
-
Patent number: 7803786Abstract: The present invention comprises pharmaceutical compositions comprising a co-crystal of an API and a co-crystal former, and methods of making and using the same.Type: GrantFiled: June 16, 2005Date of Patent: September 28, 2010Assignees: Transform Pharmaceuticals, Inc., University of South FloridaInventors: Jennifer McMahon, Matthew Peterson, Michael J. Zaworotko, Tanise Shattock, Magali Bourghol Hickey
-
Publication number: 20100210731Abstract: Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.Type: ApplicationFiled: February 19, 2010Publication date: August 19, 2010Applicant: Cephalon, Inc.Inventors: Magali Bourghol Hickey, Matthew Peterson, Orn Almarsson, Mark Oliveira
-
Patent number: 7671093Abstract: A mixed co-crystal comprising an API, a first co-crystal former, and a second co-crystal former which is isomorphically substitutable with said first co-crystal former is described. A pharmaceutical composition comprising a mixed co-crystal, methods of making mixed co-crystals, and methods of using mixed co-crystals are also described.Type: GrantFiled: May 27, 2005Date of Patent: March 2, 2010Assignee: Transform Pharmaceuticals, Inc.Inventors: Matthew Peterson, Magali Bourghol Hickey, Mark Oliveira, Örn Almarsson, Julius Remenar
-
Patent number: 7566805Abstract: Co-crystals and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and several important physical properties are modulated. The solubility, dissolution, bioavailability, dose response, and stability of modafinil can be modulated to improve efficacy in pharmaceutical compositions.Type: GrantFiled: September 4, 2004Date of Patent: July 28, 2009Assignee: Cephalon, Inc.Inventors: Magali Bourghol Hickey, Matthew Peterson, Orn Almarsson, Mark Oliveira
-
Publication number: 20090018202Abstract: Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.Type: ApplicationFiled: February 1, 2005Publication date: January 15, 2009Applicant: Cephalon, Inc.Inventors: Magali Bourghol Hickey, Matthew Peterson, Orn Almarsson, Mark Oliveira
-
Publication number: 20070299033Abstract: The present invention comprises pharmaceutical compositions comprising a co-crystal of an API and a co-crystal former, and methods of making and using the same.Type: ApplicationFiled: June 16, 2005Publication date: December 27, 2007Applicants: Trans Form Pharmaceuticals, Inc., University of South FloridaInventors: Jennifer McMahon, Matthew Peterson, Michael Zaworotko, Tanise Shattock, Magali Bourghol Hickey
-
Publication number: 20070059356Abstract: A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphinic acid, phosphonic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, 0-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.Type: ApplicationFiled: February 26, 2004Publication date: March 15, 2007Inventors: Örn Almarsson, Magali Bourghol Hickey, Matthew Peterson, Michael Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
-
Publication number: 20070026078Abstract: A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.Type: ApplicationFiled: September 11, 2003Publication date: February 1, 2007Applicants: TransForm Pharmaceuticals, Inc., University of South Florida, The Regents of the University of MichiganInventors: Orn Almarsson, Magali Bourghol Hickey, Matthew Peterson, Michael Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
-
Publication number: 20060223794Abstract: The invention provides novel soluble olanzapine forms. These forms include salts, co-crystals, and solvates of olanzapine. The invention also provides novel pharmaceutical compositions comprising these novel soluble forms and related methods of treatment. Compositions and methods of the invention of the invention are useful in the treatment of psychosis and functional bowel disorders.Type: ApplicationFiled: March 31, 2004Publication date: October 5, 2006Applicant: TransForm Phamaceuticals, Inc.Inventors: Magali Bourghol Hickey, Julius Remenar
-
Publication number: 20050267209Abstract: A mixed co-crystal comprising an API, a first co-crystal former, and a second co-crystal former which is isomorphically substitutable with said first co-crystal former is described. A pharmaceutical composition comprising a mixed co-crystal, methods of making mixed co-crystals, and methods of using mixed co-crystals are also described.Type: ApplicationFiled: May 27, 2005Publication date: December 1, 2005Inventors: Matthew Peterson, Magali Bourghol Hickey, Mark Oliveira, Orn Almarsson, Julius Remenar